drugset / Trial / NCT05452213
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
Phase 4
Recruiting
1000 enrolled
Institut fuer Frauengesundheit
AGO Breast Study Group e.V. · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with ribociclib and standard of care endocrine treatment according to SmPC.
Timeline
- Start
- 2022-10-12
- Primary completion
- 2024-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribociclib | Small molecule | 600 mg | — |